PROGRAM SNAPSHOT

Sana Biotechnology — SC451

🧪 Not Yet Scored Preclinical

Sana's next-generation clinical candidate — no efficacy data yet, and a different product from UP421.

What's actually shown: Sana's stem-cell-derived successor product, developed with Mayo Clinic. Still preclinical, with no public efficacy data disclosed — staying Not Yet Scored is the correct call, not a gap to close, until Sana publishes results. This is a different product from UP421 (the proof-of-concept covered on this site) — never treat SC451 as sharing UP421's results.

Last verified: 2026-08-24. Sources: Sana pipeline page.

This is a Program Snapshot, not yet a full Trial Report Card — a full Report Card means the deeper eligibility, risk, and enrollment research we do for each Cure Radar post. Follow @t1dcureintelligence for the full breakdown when this program gets its own deep-dive.

← Back to the full leaderboard